Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Marie Skłodowska-Curie Action · Running

DiagMDS Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility

Coordinator
Idryma Iatroviologikon Ereunon Akademias Athinon, Greece
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€1.3m
Total cost
—
Partners
17 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101300062

What the project is doing

In the project's own words, from its summary on CORDIS.

The DiagMDS project aims to enhance training and lifelong learning opportunities for research and innovation staff by providing structured, cross-sectoral and interdisciplinary exchanges for mobility-driven skill development. Myelodysplastic syndrome (MDS) is a heterogeneous group of hematopoietic disorders characterised by dysplasia of blood cell lineages, cytopenia, functional abnormalities, and stem cell-derived defects in differentiation, proliferation, and maturation of myeloid lineages.

Despite various advances in the field, early and accurate diagnosis remains challenging, as peripheral blood (PB) counts and morphological features overlap with those of anemias. Current diagnostics rely on an integration of PB, bone marrow (BM) findings, karyotyping, and detection of specific mutations via next-generation sequencing. DiagMDS will address this unmet clinical need by developing novel, non-invasive methods for accurate MDS diagnosis in the PB.

DiagMDS will study the immune microenvironment, genome architecture, chromatin accessibility, methylation, EVs cargo, mitochondrial DNA and metabolome in PB of MDS patients. The project will then develop novel in silico approaches to obtain patient-specific omic signatures and chromosomal scaffolds. It will utilise AI-based methods for integrating imaging, omics, and clinical data. Following validation of key findings, diagnostic biomarkers/profiles are expected to be defined.

The application of such cutting-edge experimental, computational and clinically relevant approaches will significantly contribute to MDS diagnosis, while strengthening staff skills, knowledge transfer, and research excellence.

Topics

Who is involved

OrganisationCityCountryRole
Idryma Iatroviologikon Ereunon Akademias AthinonAthinaGreeceCoordinator
Cellock LtdNicosiaCyprusParticipant
Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen RechtsGoettingenGermanyParticipant
Enios Applications Idiotiki Kefalaiouchiki EtaireiaKallitheaGreeceParticipant
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceParticipant
Exelixis Diacheirisi Erevnas Kai Epikoinonia EeGerakas AttikiGreeceAssociatedpartner
Afekta Technologies LtdSiilinjarviFinlandParticipant
Centre National De La Recherche Scientifique CNRSParisFranceAssociatedpartner
Bio InzeneringSkopjeNorth MacedoniaAssociatedpartner
Company for Research and Development Fingerprint Diagnostics Llc SkopjeSkopjeNorth MacedoniaParticipant
Nuclein DOOELSkopjeNorth MacedoniaAssociatedpartner
Special Hospital for Surgical Diseases Zan Mitrev, SkopjeSkopjeNorth MacedoniaAssociatedpartner
Ingenix.ai sp. z o.o.WarsawPolandParticipant
Politechnika WarszawskaWarszawaPolandParticipant
Izmir Biyotip Ve Genom MerkeziİzmirTürkiyeAssociatedpartner
Meriel Biosciences Anonim SirketiKonak/IzmirTürkiyeParticipant
King's College LondonLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI